New treatment for horizontal bone loss in the mouth
MINE-MS for horizontal bone loss treatment
This study is testing a new injectable treatment designed to help rebuild the bone lost due to gum disease, which can lead to tooth loss, and it aims to make this treatment even better by adding a special ingredient that helps attract healing cells to the area.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Missouri-Columbia NIH-funded |
| Lab location | 1 site (Columbia, United States) |
| Project ID | NIH-10800666 on NIH RePORTER |
What this research studies
This research focuses on developing a novel treatment for horizontal alveolar bone loss caused by periodontitis, a common oral disease that leads to tooth loss in adults. The approach involves creating an innovative injectable biomaterial called MINE-MS, which mimics the extracellular matrix and promotes bone regeneration. The study aims to enhance the effectiveness of this treatment by incorporating a specific peptide that attracts stem cells essential for healing. Patients may benefit from improved outcomes in managing their oral health and preventing tooth loss.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who are experiencing horizontal alveolar bone loss due to periodontitis.
Not a fit: Patients with vertical bone loss or those who do not have periodontitis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients suffering from periodontitis-related bone loss, potentially preserving their teeth.
How similar studies have performed: While there has been some research on bone regeneration techniques, the specific approach using MINE-MS and the E7 peptide is novel and has not been extensively tested.
Where this research is happening
Columbia, United States
- University of Missouri-Columbia — Columbia, United States (Active)
Researchers
- Principal investigator: Liu, Xiaohua — University of Missouri-Columbia
- Study coordinator: Liu, Xiaohua
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.